PUBLIC COMPANY
save$GERNGERON CORP
$GERN1.5500-2.52%Foster City, CA, USupdated 8h ago
community read0 votes
pipeline
2
marketed
1
phase 3
0
catalysts ytd
4
approvals ytd
1
recalls ytd
0
Pipeline(2)
pipeline depth2 products
1Marketed1Unknown
Upcoming
Recent(90d)
view all catalysts →Active trials
- phase3A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment
- phase1A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Clinical Activity of Imetelstat in Combination With Ruxolitinib in Participants With Myelofibrosis
- phase3Study to Evaluate Imetelstat (GRN163L) in Participants With International Prognostic Scoring System (IPSS) Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS)
- —Expanded Access for Treatment With Imetelstat
Insider activity
source: SEC Form 4routine RSU / option mechanics (4)
- Apr 13, 26grantWilliams Timothy · EVP and Chief Legal Officer2,500,000 sh
- Mar 31, 26grantSpiegel Robert J. · 5,243 sh
- Mar 25, 26grantChinoporos Constantine · 270,000 sh
- Mar 25, 26grantAndrews Patricia S · 270,000 sh
🐶 Hiring Signal
next earnings Nov 4, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that